John Forsyth Biography and Net Worth

John D. Forsyth has served as a director of Baxter since 2003.

Forsyth is the former chairman and chief executive officer of Wellmark Blue Cross Blue Shield, a healthcare insurance provider for residents of Iowa and South Dakota. He served as Wellmark's chairman from 2000 through 2020, and as Wellmark's chief executive officer from 1996 through 2020. Prior to that, he spent 26 years at the University of Michigan, holding various positions, including president and chief executive officer of the University of Michigan Health System. Forsyth currently serves as a director of the National Institute of Healthcare Management. He previously served as a director of Baxalta (before it was acquired by Shire in June 2016).

What is John D. Forsyth's net worth?: The estimated net worth of John D. Forsyth is at least $1.36 million as of September 14th, 2020. Mr. Forsyth owns 34,279 shares of Baxter International stock worth more than $1,362,247 as of April 19th. This net worth approximation does not reflect any other investments that Mr. Forsyth may own. Learn More about John D. Forsyth's net worth.
How do I contact John D. Forsyth?: The corporate mailing address for Mr. Forsyth and other Baxter International executives is One Baxter Parkway DF2-1W, Deerfield IL, 60015. Baxter International can also be reached via phone at (224) 948-2000 and via email at [email protected]. Learn More on John D. Forsyth's contact information.
Has John D. Forsyth been buying or selling shares of Baxter International?: John D. Forsyth has not been actively trading shares of Baxter International during the last ninety days. Most recently, John D. Forsyth sold 310 shares of the business's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $83.59, for a transaction totalling $25,912.90. Following the completion of the sale, the director now directly owns 34,279 shares of the company's stock, valued at $2,865,381.61. Learn More on John D. Forsyth's trading history.
Who are Baxter International's active insiders?: Baxter International's insider roster includes Giuseppe Accogli (SVP), John Forsyth (Director), Andrew Frye (SVP), James Gavin, III (Director), Jacqueline Kunzler (SVP), Sean Martin (SVP), Jeanne Mason (SVP), Brian Stevens (CAO), and Albert Stroucken (Director). Learn More on Baxter International's active insiders.

John D. Forsyth Insider Trading History at Baxter International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2020	Sell	310	$83.59	$25,912.90	34,279
6/15/2020	Sell	1,500	$82.95	$124,425.00	35,398
12/13/2019	Sell	1,500	$83.64	$125,460.00	30,078
9/13/2019	Sell	180	$87.76	$15,796.80	31,701
6/13/2019	Sell	1,320	$78.21	$103,237.20	32,779
3/13/2019	Sell	1,500	$75.92	$113,880.00	31,703
12/13/2018	Sell	1,500	$67.02	$100,530.00	31,640
8/25/2017	Sell	9,440	$61.76	$583,014.40	32,444
2/8/2017	Sell	4,280	$48.35	$206,938.00	31,338
5/2/2016	Sell	1,887	$44.38	$83,745.06	26,320
4/4/2016	Sell	1,887	$41.75	$78,782.25	26,315

John D. Forsyth Buying and Selling Activity at Baxter International

Baxter International Company Overview

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Today's Range

Now: $39.74

$39.60

$40.08

50 Day Range

MA: $41.80

$39.51

$43.77

2 Week Range

Now: $39.74

$31.01

$50.21

Volume

574,318 shs

Average Volume

3,652,955 shs

Market Capitalization

$20.18 billion

P/E Ratio

7.61

Dividend Yield

2.93%

Beta

0.62

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here